High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease.
Cardiac biomarkers
Metabolic dysfunction-associated steatotic liver disease
Myocardial injury.
Nonalcoholic fatty liver disease
Troponin
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 08 2024
22 08 2024
Historique:
received:
29
04
2024
accepted:
20
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Given the global high prevalence of MASLD and its poor CVD prognosis, it is essential to perform risk stratification for MASLD patients. The specific impact of High Sensitivity Troponins (hs-cTn ) on mortality in MASLD patients remains unexplored. The NHANES databases from 1999 to 2004, which include data on high-sensitivity cardiac troponin (hs-cTn) levels and comorbidities, were linked with the most recent mortality dataset. Myocardial injury was determined using the 99th upper reference limits (URL) for hs-cTn. Our study included 3460 MASLD patients. The mean follow-up duration was 192 months, during which 1074 (23%) MASLD participants died from all-cause mortality, and 363 (7.3%) died from CVD mortality. Our findings indicate that MASLD patients with elevated levels of hs-cTnT (> 99th URL) exhibit increased risks of all-cause mortality [adjusted hazard ratio (aHR) = 1.93] and CVD mortality (aHR = 2.4). Similar results were observed for hs-cTnI, where the aHRs for all-cause mortality and CVD mortality were 2.03 and 2.97, respectively. Furthermore, we identified a nonlinear dose-response relationship between hs-cTn levels and the risk of mortality (P for nonlinearity < 0.001). Our findings suggest that hs-cTn can predict mortality risk in MASLD, aiding clinicians in risk-stratifying this population. Therefore, we recommend considering hs-cTn detection in individuals with MASLD to effectively assess their future mortality risk.
Identifiants
pubmed: 39174636
doi: 10.1038/s41598-024-70645-7
pii: 10.1038/s41598-024-70645-7
doi:
Substances chimiques
Biomarkers
0
Troponin
0
Troponin T
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19541Informations de copyright
© 2024. The Author(s).
Références
Zhu, J. Z. et al. Prevalence of nonalcoholic fatty liver disease and economy. Dig. Dis. Sci. 60 (11), 3194–3202 (2015).
doi: 10.1007/s10620-015-3728-3
pubmed: 26017679
Francque, S. M., van der Graaff, D. & Kwanten, W. J. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J. Hepatol. 65 (2), 425–443 (2016).
doi: 10.1016/j.jhep.2016.04.005
pubmed: 27091791
Konyn, P., Ahmed, A. & Kim, D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29 (Suppl), S43-s57 (2023).
doi: 10.3350/cmh.2022.0351
pubmed: 36417893
Younossi, Z. M. et al. Serum biomarkers are associated with atherosclerotic cardiovascular disease among patients with nonalcoholic fatty liver disease undergoing elective angiography. Clin. Gastroenterol. Hepatol. 20 (5), e1149–e1156 (2022).
doi: 10.1016/j.cgh.2021.08.038
pubmed: 34464720
Maechler, M. et al. 472-P: Pro-B-type natriuretic peptide strongly predicts future cardiovascular events in cardiovascular disease patients with NAFLD as well as in those without NAFLD. Diabetes 72 (Supplement_1) (2023). .
Welsh, P. et al. Cardiac troponin T and troponin I in the general population. Circulation 139 (24), 2754–2764 (2019).
doi: 10.1161/CIRCULATIONAHA.118.038529
pubmed: 31014085
pmcid: 6571179
Omland, T. et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 61 (12), 1240–1249 (2013).
doi: 10.1016/j.jacc.2012.12.026
pubmed: 23414791
Jia, X. et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 139 (23), 2642–2653 (2019).
doi: 10.1161/CIRCULATIONAHA.118.038772
pubmed: 31030544
pmcid: 6546524
McEvoy, J. W. et al. High-sensitivity troponins and mortality in the general population. Eur. Heart J.44 (28), 2595–2605 (2023).
doi: 10.1093/eurheartj/ehad328
pubmed: 37264651
pmcid: 10361011
Das, S. R. et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology solution set oversight committee. J. Am. Coll. Cardiol.76 (9), 1117–1145 (2020).
doi: 10.1016/j.jacc.2020.05.037
pubmed: 32771263
pmcid: 7545583
Forlano, R. et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 15 (10), e0240400 (2020).
doi: 10.1371/journal.pone.0240400
pubmed: 33031439
pmcid: 7544083
Zipf, G. et al. National Health and Nutrition Examination Survey: Plan and operations, 1999–2010. Vital Health Stat.1 (56), 1–37 (2013).
Rinella, M. E. et al. A multisociety Delphi Consensus Statement on new fatty liver disease nomenclature. Hepatology. 78 (6), 1966–1986 (2023).
doi: 10.1097/HEP.0000000000000520
pubmed: 37363821
Bedogni, G. et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol.6, 33 (2006).
doi: 10.1186/1471-230X-6-33
pubmed: 17081293
pmcid: 1636651
Bashar, H. et al. Association of myocardial injury with adverse long-term survival among cancer patients. Eur. J. Prev. Cardiol. (2024).
Thygesen, K. et al. Fourth universal definition of myocardial infarction (2018). Circulation. 138 (20), e618–e651 (2018).
doi: 10.1161/CIR.0000000000000617
pubmed: 30571511
Franklin, B. A. et al. Physical activity and cardiorespiratory fitness as modulators of health outcomes: A compelling research-based case presented to the medical community. Mayo Clin Proc. 98(2), 316–331 (2023).
Laukkanen, J. A., Isiozor, N. M. & Kunutsor, S. K. Objectively assessed cardiorespiratory fitness and all-cause mortality risk: An updated meta-analysis of 37 cohort studies involving 2,258,029 participants. Mayo Clin Proc. 97(6), 1054–1073 (2022).
Cabanas-Sánchez, V. et al. Physical activity and cause-specific cardiovascular mortality among people with and without cardiovascular disease: A cohort study of 0.6 million US adults. Mayo Clin Proc. 99(4), 564–577 (2024).
Gebel, K. et al. Effect of moderate to vigorous physical activity on all-cause mortality in middle-aged and older Australians. JAMA Intern. Med.175 (6), 970–977 (2015).
doi: 10.1001/jamainternmed.2015.0541
pubmed: 25844882
Stamatakis, E. et al. Sitting time, physical activity, and risk of mortality in adults. J. Am. Coll. Cardiol.73 (16), 2062–2072 (2019).
doi: 10.1016/j.jacc.2019.02.031
pubmed: 31023430
Bull, F. C. et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med.54 (24), 1451–1462 (2020).
doi: 10.1136/bjsports-2020-102955
pubmed: 33239350
Johnson, C. L. et al. National Health and Nutrition Examination Survey: Analytic guidelines, 1999–2010. Vital Health Stat. 2(161), 1–24 (2013).
McEvoy, J. W. et al. Four high sensitivity troponin assays and mortality in US adults with cardiovascular disease: The National Health and Nutrition Examination Survey, 1999–2004. Am. J. Prev. Cardiol.17, 100631 (2024).
doi: 10.1016/j.ajpc.2023.100631
pubmed: 38304389
pmcid: 10832369
Aimo, A. et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: An individual patient data meta-analysis. Circulation. 137 (3), 286–297 (2018).
doi: 10.1161/CIRCULATIONAHA.117.031560
pubmed: 29335288
McEvoy, J. W. et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.1 (5), 519–528 (2016).
doi: 10.1001/jamacardio.2016.0765
pubmed: 27439107
pmcid: 5084093
Cho, H. et al. Frequency histograms of three high-sensitivity cardiac troponin assays in a reference population. J. Clin. Lab. Anal.36 (6), e24432 (2022).
doi: 10.1002/jcla.24432
pubmed: 35441734
pmcid: 9169213
Eggers, K. M. et al. Cardiac troponin I levels in an elderly population from the community–The implications of sex. Clin. Biochem.48 (12), 751–756 (2015).
doi: 10.1016/j.clinbiochem.2015.04.013
pubmed: 25916815
Gore, M. O. et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J. Am. Coll. Cardiol.63 (14), 1441–1448 (2014).
doi: 10.1016/j.jacc.2013.12.032
pubmed: 24530665
pmcid: 3984900
McRae, A. et al. Sex-specific, high-sensitivity cardiac troponin T cut-off concentrations for ruling out acute myocardial infarction with a single measurement. Cjem. 21 (1), 26–33 (2019).
doi: 10.1017/cem.2018.435
pubmed: 30261938
Michailovich Chaulin, A. Diagnostic role and methods of detection of cardiac troponins: An opinion from historical and current points of view. Curr. Cardiol. Rev.19 (1), e100622205865 (2023).
doi: 10.2174/1573403X18666220610164946
pubmed: 35702796
Klinkenberg, L. J. et al. Circulating cardiac troponin T exhibits a diurnal rhythm. J. Am. Coll. Cardiol.63 (17), 1788–1795 (2014).
doi: 10.1016/j.jacc.2014.01.040
pubmed: 24583293
Vroemen, W. H. M. et al. Cardiac troponin T: Only small molecules in recreational runners after marathon completion. J. Appl. Lab. Med.3 (5), 909–911 (2019).
doi: 10.1373/jalm.2018.027144
pubmed: 31639766
Eggers, K. M. & Lindahl, B. Application of cardiac troponin in cardiovascular diseases other than acute coronary syndrome. Clin. Chem.63 (1), 223–235 (2017).
doi: 10.1373/clinchem.2016.261495
pubmed: 28062620
Parikh, N. I. et al. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch. Intern. Med.166 (17), 1884–1891 (2006).
doi: 10.1001/archinte.166.17.1884
pubmed: 17000946
Sedighi, S. M. et al. Elevated cardiac troponin levels in geriatric patients without ACS: Role of comorbidities. CJC Open.3 (3), 248–255 (2021).
doi: 10.1016/j.cjco.2020.07.017
pubmed: 33778441
Wan Nur Aimi, W. M. Z. et al. Elevation of highly sensitive cardiac troponin T among end-stage renal disease patients without acute coronary syndrome. Malays J. Med. Sci.28 (5), 64–71 (2021).
pubmed: 35115888
pmcid: 8793973
Chaulin, A. & Duplyakov, D. The main causes and mechanisms of the formation of false positive results of troponin immunotests. East. Eur.11, 132–147 (2022).
Salaun, E. et al. Role of antitroponin antibodies and macrotroponin in the clinical interpretation of cardiac troponin. J. Am. Heart Assoc.13 (12), e035128 (2024).
doi: 10.1161/JAHA.123.035128
pubmed: 38879450
pmcid: 11255741
deFilippi, C. R. et al. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J. Am. Coll. Cardiol.60 (24), 2539–2547 (2012).
doi: 10.1016/j.jacc.2012.08.1006
pubmed: 23158528
pmcid: 3591516
Packer, M. et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 131 (1), 54–61 (2015).
doi: 10.1161/CIRCULATIONAHA.114.013748
pubmed: 25403646
Everett, B. M. et al. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: Impact of statin therapy. Circulation. 131 (21), 1851–1860 (2015).
doi: 10.1161/CIRCULATIONAHA.114.014522
pubmed: 25825410
pmcid: 4444427
Gravning, J. et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: Results from the CORONA trial. Circ. Heart Fail.7 (1), 96–103 (2014).
doi: 10.1161/CIRCHEARTFAILURE.113.000450
pubmed: 24284025
Murphy, S. P. et al. Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction. Circ. Heart Fail.14 (6), e008410 (2021).
doi: 10.1161/CIRCHEARTFAILURE.120.008410
pubmed: 33998243
Cheng, P. N. et al. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan Position Statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases. Clin. Mol. Hepatol.30 (1), 16–36 (2024).
doi: 10.3350/cmh.2023.0315
pubmed: 37793641
Kavsak, P. A. et al. Macrocomplexes and high-sensitivity cardiac troponin assays in samples stored for over 15 years. Clin. Chim. Acta. 505, 6–8 (2020).
doi: 10.1016/j.cca.2020.02.013
pubmed: 32070727
Ho, A. et al. Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). J. Clin. Lipidol. (2024).